DUR 928

Drug Profile

DUR 928

Alternative Names: DUR-928; DV-928

Latest Information Update: 17 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator DURECT Corporation
  • Class Small molecules
  • Mechanism of Action Inflammation mediator modulators; Lipid modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Primary sclerosing cholangitis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Acute kidney injury; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Psoriasis
  • Preclinical Liver disorders; Stroke

Most Recent Events

  • 08 Aug 2017 DURECT Corporation completes a phase I trial in Acute kidney injury in Australia (Parenteral) (ACTRN12616000389404)
  • 08 Aug 2017 DUR 928 receives Orphan Drug status for Primary sclerosing cholangitis in USA
  • 22 Jun 2017 DURECT Corporation completes a phase I C928-018 trial for Non-alcoholic steatohepatitis (In volunteers) in USA (ACTRN12617000579392)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top